PAVmed, Inc. (PAVM)

PAVmed announced a 1-for-30 reverse stock split on December 30, 2025, following amendment approval on December 5, 2025. The company's price target was decreased by 12.50% to $10.71 on December 21, 2025. Its subsidiary, Lucid Diagnostics, announced positive data from esophageal precancer detection on December 9, 2025, and was recognized as a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree on November 20, 2025. PAVmed provided a business update and reported its third-quarter financial results on November 13, 2025, with Lucid Diagnostics reporting $1.2 million in EsoGuard revenue. PAVmed was granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule on July 30, 2025. The stock has experienced significant volatility, reaching a 52-week low of $0.6 in December 2024.

Specific information regarding the demand seasonality for PAVmed, Inc.'s products and services is not explicitly detailed. The company operates in the medical technology sector, which may experience demand fluctuations based on healthcare cycles, budget allocations, and disease prevalence, but concrete seasonal trends for PAVmed's specific offerings are not provided.

PAVmed, Inc. is a diversified commercial-stage medical technology holding company that develops and commercializes innovative medical devices, diagnostics, and digital health solutions. Its business is segmented into medical devices, diagnostics, and digital health, with a mission to improve patient outcomes and reduce healthcare costs through proprietary technologies. Key products include EsoGuard® and EsoCheck® for esophageal precancer detection, CarpX® for carpal tunnel syndrome treatment, PortIO™ for vascular access, DisappEAR™ antimicrobial ear tubes, EsoCure™ for Barrett's Esophagus, Veris™ Cancer Care Platform for personalized cancer care, NextCath™ self-anchoring catheter, NextFlo™ disposable infusion system, and Caldus™ disposable tissue ablation device.

PAVmed Inc. is headquartered in New York, NY, United States. It has research, development, and regulatory operations in North America and strategic partnerships in Europe, with primary operations across the U.S.

PAVmed's brand reputation is tied to its innovative medical technologies and its subsidiaries' progress. Lucid Diagnostics received positive recognition as a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree in November 2025. The company's stock has experienced significant declines and faced Nasdaq compliance issues, but there is no specific information detailing negative events directly impacting PAVmed's overall brand reputation beyond general market perception.

Institutional investors hold approximately 4.95% of PAVmed's shares, with major holders including First Manhattan Co, Vanguard Group Inc, Jane Street Group, Llc, Geode Capital Management, Llc, and BlackRock, Inc. Individual insider ownership is substantial, accounting for approximately 50.74% of the company, with Ira Scott Greenspan being the largest individual shareholder. Retail investors hold approximately 44.31% of the company.